Shares of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) plunged $27.18, or 75.5%, to close at $8.82 on top-line results from the phase III study called Intrigue with Qinlock (ripretinib) in gastrointestinal stromal tumors (GIST) previously treated with kinase inhibitor Gleevec (imatinib, Novartis AG).